OptimizeRx (OPRX) Cost of Revenue (2013 - 2026)

OptimizeRx has disclosed Cost of Revenue across 14 years of filings, most recently posting $4.8 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 54.39% year-over-year to $4.8 million; the TTM figure through Jun 2026 stood at $26.4 million (down 29.17% YoY), while the FY2025 annual figure was $35.8 million, up 9.42% from the prior year.
• Cost of Revenue came in at $4.8 million for Q2 2026 at OptimizeRx, down from $4.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10.6 million in Q2 2025 to a low of $4.8 million in Q2 2026.
• Average Cost of Revenue over 5 years is $7.2 million, with a median of $7.2 million recorded in 2022.
• Year-over-year, Cost of Revenue surged 48.56% in 2025 and slumped 54.39% in 2026.
• Over 5 years, Cost of Revenue stood at $7.2 million in 2022, then surged by 46.22% to $10.5 million in 2023, then declined by 2.23% to $10.3 million in 2024, then dropped by 20.93% to $8.1 million in 2025, then sank by 40.83% to $4.8 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $4.8 million in Q2 2026, $4.9 million in Q1 2026, and $8.1 million in Q4 2025.